Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

- PMLiVE

NHS patients set to be denied Opdivo and Kadcyla

NICE rejects BMS and Roche cancer treatments

- PMLiVE

AZ takes majority stake in cancer drug developer Acerta

Will pay $4bn for a 55% share in the Dutch biopharma company

- PMLiVE

BMS’ Empliciti approved by FDA for multiple myeloma

Clearedfor use in with Celgene's Revlimid and corticosteroid dexamethasone

Bristol-Myers Squibb (BMS) building

Bump in the road slows momentum for BMS’ Opdivo

FDAturns down the cancer treatment for a form of melanoma

Bristol-Myers Squibb (BMS) building

Opdivo cleared for kidney cancer and first-line melanoma

First drug to show survival benefit in kidney cancer since 2007

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

Bristol-Myers Squibb (BMS) building

BMS closer to kidney cancer approval for Opdivo

Wins priority review for renal cell carcinoma

CAR-T cancer therapy passes milestone

Belgianbiotech Celyad's cancer immunotherapy will now be tested at higher doses

Bristol-Myers Squibb (BMS) building

BMS pulls ahead of Merck in quarterly PD-1 inhibitor sales

Supports analysts prediction BMS' Opdivo will become market leader

Bristol-Myers Squibb (BMS) building

First data backs efficacy of BMS’ novel HIV drug

Could provide new treatment for those resistant to antiretroviral therapy

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

Bristol-Myers Squibb (BMS) building

BMS bags US approval for Opdivo and Yervoy combo

Marks first approval for joint use of two immuno-oncology drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links